This post was originally published on this site
Pfizer Inc. on Tuesday said a second Phase 3 study of its recently acquired investigational drug etrasimod met the main endpoints in the treatment of moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease.
The New York drugmaker
PFE,
said patients taking etrasimod achieved statistically significant improvements in the co-primary endpoints of clinical remission at weeks 12 and 52 compared with placebo.
Pfizer also reported statistically significant improvements in all key secondary endpoints at both 12 and 52 weeks, adding that etrasimod showed a safety profile consistent with previous studies.
The company said it expects to initiate regulatory filings later this year for etrasimod, the lead drug candidate of Arena Pharmaceuticals, which Pfizer recently acquired for $6.7 billion.
Pfizer last week reported positive 12-week findings from a separate Phase 3 etrasimod trial.
Write to Colin Kellaher at colin.kellaher@wsj.com
